top of page

Latest Articles:
Stay in the Know

StemCyte's CEO explains why the company is ready for an IPO. In addition to operating a multi-national hybrid bank, StemCyte is also manufacturing immunotherapies from cord blood and is one of the industry's leaders in running clinical trials with cord blood.

Parent's Guide to Cord Blood Interview with StemCyte CEO Tong-Young Lee PhD

May 2024

"I didn't expect that the umbilical cord blood saved for the child would actually save the child's life 19 years later!" said the father of Xiaoan, an aplastic anemia patient, excitedly. To learn more about cord blood banking.

A Parent's Guide To Cord Blood Article...

Cured by his own cord blood 19 years later 

October 2023

In this story, a child that underwent a prolonged cardiac arrest was resuscitated but remained in a vegetative state because of the pause in blood flow to his brain. After an infusion of his own cord blood, he experienced a remarkable recovery over the next three years that has been published in the medical literature.

A Parent's Guide To Cord Blood Article...

Cord Blood Rescue After Cardiac Arrest

Aug. 2023

As international demand for starting substances for use in cell therapy emerges, California-based regenerative therapeutics company StemCyte announced it has signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte has agreed to supply the necessary cellular raw materials for allogeneic cell therapy product development worldwide. 

StemCyte signs a cooperation agreement with US immune cell therapy company

June 2023

Peleg had a typical case of autism with regression. His parents decided to try cell therapy. Before and after videos document his rapid improvement in language skills. 

A Parent's Guide to Cord Blood Article...

Peleg's Story of Cell Therapy for Autism

Jun 2023

Salvador is a 5-year-old boy from Portugal diagnosed with Autism Spectrum Disorder who received cord blood therapy in the US through the Expanded Access program at Duke. 


A Parent's Guide To Cord Blood Article...

Salvador’s Story: Expanded Access for Autism

May 2023

Covid-19 - StemCyte

StemCyte announced it has officially begun recruiting patients under a US Food and Drug Administration (FDA) approved Phase IIa human clinical trial in the United States. This is the world's first Phase II trial using umbilical cord blood cells to treat Post-COVID syndrome.

The first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients

May 2023

A Once In A Lifetime Opportunity To Preserve Your Baby's Stem Cells

Stem Cyte provides the most comprehensive Cord Blood banking packages.

bottom of page